Use of Taleum 1-mg inhalation aerosol in bronchial asthma patients.
The effect of 2 sodium chromoglycate products: Taleum 1-mg aerosol (EGIS) and Intal powder capsule (Fisons) has been examined for 4-4 weeks in 15 extrinsic asthma patients by cross-over self-controlled open method. The patients measured peak expiratory flow (PEF) 5 times daily and recorded the time of dyspneic periods in a diary as well as the amount of bronchodilator spray (Berodual, Boehringer) used as adjuvant therapy during dyspnea. The results of the weekly evaluation of the complaints and PEF values proved that both drugs are similarly effective in the prevention of dyspnea caused by bronchial asthma. The adjuvant inhalation betamimetic and anticholinergic drug requirement was lowered, the number, intensity and total time of dyspneic episodes decreased. In the course of the examinations Taleum 1-mg inhalation aerosol proved to be of identical value with Intal powder capsule. Some patients who do not like powder inhalation found the Taleum aerosol drug form to be more advantageous. Side-effect of drug was not observed.